scholarly journals O17‐5: Soluble TIM‐4 levels in serum are associated with severe asthma phenotype

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 47-47
Keyword(s):  
Severe Asthma ◽  
Asthma Phenotype

scholarly journals Pharmacological Rationale for Targeting IL-17 in Asthma

2021 ◽  
Vol 2 ◽  
Author(s):  
Siti Farah Rahmawati ◽  
Maurice te Velde ◽  
Huib A. M. Kerstjens ◽  
Alexander S. S. Dömling ◽  
Matthew Robert Groves ◽  
...  
Keyword(s):  
Severe Asthma ◽  
Inhaled Corticosteroids ◽  
Current Knowledge ◽  
Experimental Models ◽  
Airflow Limitation ◽  
Interleukin 17 ◽  
Asthma Phenotype ◽  
T Helper 2 ◽  
Bronchial Biopsies

Asthma is a respiratory disease that currently affects around 300 million people worldwide and is defined by coughing, shortness of breath, wheezing, mucus overproduction, chest tightness, and expiratory airflow limitation. Increased levels of interleukin 17 (IL-17) have been observed in sputum, nasal and bronchial biopsies, and serum of patients with asthma compared to healthy controls. Patients with higher levels of IL-17 have a more severe asthma phenotype. Biologics are available for T helper 2 (Th2)-high asthmatics, but the Th17-high subpopulation has a relatively low response to these treatments, rendering it a rather severe asthma phenotype to treat. Several experimental models suggest that targeting the IL-17 pathway may be beneficial in asthma. Moreover, as increased activation of the Th17/IL-17 axis is correlated with reduced inhaled corticosteroids (ICS) sensitivity, targeting the IL-17 pathway might reverse ICS unresponsiveness. In this review, we present and discuss the current knowledge on the role of IL-17 in asthma and its interaction with the Th2 pathway, focusing on the rationale for therapeutic targeting of the IL-17 pathway.

Aerobic Exercise Improves Asthma Phenotype in a Model of Severe Asthma: Involvement of Kinins

2021 ◽  
Author(s):  
Maysa A. R. Brandao-Rangel ◽  
Renilson Moraes-Ferreira ◽  
Anamei Silva-Reis ◽  
Victor Hugo Souza Palmeira ◽  
Francine Maria Almeida ◽  
...  
Keyword(s):  
Aerobic Exercise ◽  
Severe Asthma ◽  
Asthma Phenotype

Biologics for oral corticosteroid-dependent asthma

2020 ◽  
Vol 41 (3) ◽  
pp. 151-157
Author(s):  
İnsu Yılmaz
Keyword(s):  
Severe Asthma ◽  
Oral Corticosteroid ◽  
Real Life ◽  
Severe Atopic Dermatitis ◽  
Double Blind ◽  
Eosinophilic Asthma ◽  
Asthma Phenotype ◽  
Severe Eosinophilic Asthma ◽  
Term Administration

Background: Oral corticosteroid (OCS) dependent asthma is one of the severe asthma phenotypes that requires personalized treatment. Objective: To review the role of biologic treatments in OCS-dependent asthma. Methods: A nonsystematic review was performed of emerging multiple novel biologics for potential treatment of OCS-dependent asthma. Results: The serious adverse effects of OCS can be seen as a result of their regular long-term administration. Anti‐interleukin (IL) 5 (mepolizumab), anti‐IL-5R (benralizumab), and anti‐IL-4Rα (dupilumab) are the therapies of choice for OCS-dependent severe asthma. Results of studies showed the efficacy of mepolizumab, benralizumab, and dupilumab, especially in patients with the OCS-dependent severe eosinophilic asthma phenotype and with nasal polyps. Dupilumab may be the therapy of choice of monoclonal antibodies in cases of moderate-severe atopic dermatitis accompanied by OCS-dependent severe asthma. For reslizumab and omalizumab, placebo controlled double-blind studies conducted with OCS-dependent patient populations are needed. Conclusion: Biologics are effective in the “OCS-dependent asthma” phenotype as add-on therapy. It seems that chronic OCS use in OCS-dependent asthma will be replaced by biologic agents that specifically target type 2 inflammation, along with a much better safety profile. However, real-life studies that compare these biologics in OCS-dependent severe asthma are urgently needed.

РАСПРОСТРАНЕННОСТЬ ФЕНОТИПОВ ТЯЖЕЛОЙ БРОНХИАЛЬНОЙ АСТМЫ НА СРЕДНЕМ УРАЛЕ

2019 ◽  
Author(s):  
E.K. Beltyukov ◽  
V.V. Naumova ◽  
V.Ch. Abdullaev ◽  
Y.A. Styazhkina ◽  
S.S. Vedenskaya
Keyword(s):  
Targeted Therapy ◽  
Severe Asthma ◽  
Bronchial Asthma ◽  
Cost Effective ◽  
Atopic Asthma ◽  
Practical Significance ◽  
Asthma Prevalence ◽  
Uncontrolled Asthma ◽  
Asthma Phenotype ◽  
Number Of Patients

Обоснование. Тяжелая БА является гетерогенным и экономически затратным заболеванием, что требует персонифицированного подхода к лечению с включением таргетной терапии, предполагающей фенотипирование астмы. Цель. Определение динамики распространенности бронхиальной астмы (БА) на Среднем Урале, в том числе тяжелой БА, и проведение фенотипирования пациентов с тяжелой БА для определения потребности в таргетной терапии. Материалы и методы. Популяционные исследования распространенности БА проводились на Среднем Урале с 2000 по 2012 г. с использованием стандартного вопросника ECRHS создавались регистры больных БА. В 2018 г. в г. Екатеринбурге проведен анализ амбулаторных карт пациентов с БА (n216). Фенотипирование БА проводилось врачом аллергологом-иммунологом. Результаты. На Среднем Урале за 17 лет число больных БА увеличилось в 2,7 раза. В популяции превалируют больные с легким течением астмы в 70,8-81 случаев преобладает атопический фенотип вне зависимости от категории населения. В структуре зарегистрированных по обращаемости больных астмой тяжелая неконтролируемая БА составляет 10,2. Каждый второй пациент с тяжелой неконтролируемой астмой имеет атопический фенотип, что составляет 5 от числа всех случаев БА каждый четвертый больной из данной группы имеет эозинофильной фенотип, что составляет 2,3 от числа всех случаев (n216). Заключение. Фенотипирование БА имеет важное прикладное значение для планирования эффективной таргетной терапии в популяции больных тяжелой неконтролируемой астмой.Topicality. Severe asthma is a heterogeneous and cost-effective disease that requires a personalized treatment approach with inclusion of targeted therapy involving the phenotyping of asthma. Objective. Determine the dynamics of asthma prevalence in the Middle Ural, including severe asthma, and phenotype patients with severe asthma for the selection of targeted therapy. Materials and methods. Population studies of bronchial asthma prevalence were conducted in the Middle Ural from 2000 to 2012 using the standard ECRHS questionnaire. Also registers of patients with asthma were created. An analysis of outpatient records of patients with asthma was conducted in Ekaterinburg in 2018. The phenotyping of bronchial asthma was carried out by an allergist-immunologist. Results. The number of patients with bronchial asthma increased by 2.7 times over 17 years in the Middle Ural. Patients with mild asthma prevail in the population. The atopic asthma phenotype predominates in 70.8-81 of cases regardless of the population category. Severe uncontrolled bronchial asthma occurs in 10.2 of cases among all patients seeking medical care. Every second patient with severe uncontrolled asthma has an atopic phenotype, which is 5 of the total number of analyzed patients with bronchial asthma. Every fourth patient with severe uncontrolled bronchial asthma has an eosinophilic phenotype, which is 2.3 of all analyzed patients with bronchial asthma (n216). Conclusion. Phenotyping of asthma has important practical significance for planning effective targeted therapy in a population of patients with severe uncontrolled asthma.

scholarly journals AEROBIC EXERCISE REDUCES SEVERE ASTHMA PHENOTYPE

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A51
Author(s):  
RENILSON FERREIRA ◽  
Anamei Silva-Reis ◽  
Sara Hamaguchi ◽  
Fernanda Degobbi Tenorio Quirino Santos Lopes ◽  
Nilsa Regina Damaceno-Rodrigues ◽  
...  
Keyword(s):  
Aerobic Exercise ◽  
Severe Asthma ◽  
Asthma Phenotype

scholarly journals Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation

2008 ◽  
Vol 104 (2) ◽  
pp. 394-403 ◽  
Author(s):  
Ronald L. Sorkness ◽  
Eugene R. Bleecker ◽  
William W. Busse ◽  
William J. Calhoun ◽  
Mario Castro ◽  
...  
Keyword(s):  
Airway Obstruction ◽  
Severe Asthma ◽  
Forced Expiratory Volume ◽  
Pathological Process ◽  
Airflow Limitation ◽  
Care Utilization ◽  
Air Trapping ◽  
Asthma Phenotype ◽  
Blood Institute ◽  
National Heart Lung

Five to ten percent of asthma cases are poorly controlled chronically and refractory to treatment, and these severe cases account for disproportionate asthma-associated morbidity, mortality, and health care utilization. While persons with severe asthma tend to have more airway obstruction, it is not known whether they represent the severe tail of a unimodal asthma population, or a severe asthma phenotype. We hypothesized that severe asthma has a characteristic physiology of airway obstruction, and we evaluated spirometry, lung volumes, and reversibility during a stable interval in 287 severe and 382 nonsevere asthma subjects from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. We partitioned airway obstruction into components of air trapping [indicated by forced vital capacity (FVC)] and airflow limitation [indicated by forced expiratory volume in 1 s (FEV1)/FVC]. Severe asthma had prominent air trapping, evident as reduced FVC over the entire range of FEV1/FVC. This pattern was confirmed with measures of residual lung volume/total lung capacity (TLC) in a subgroup. In contrast, nonsevere asthma did not exhibit prominent air trapping, even at FEV1/FVC <75% predicted. Air trapping also was associated with increases in TLC and functional reserve capacity. After maximal bronchodilation, FEV1 reversed similarly from baseline in severe and nonsevere asthma, but the severe asthma classification was an independent predictor of residual reduction in FEV1 after maximal bronchodilation. An increase in FVC accounted for most of the reversal of FEV1 when baseline FEV1 was <60% predicted. We conclude that air trapping is a characteristic feature of the severe asthma population, suggesting that there is a pathological process associated with severe asthma that makes airways more vulnerable to this component.

scholarly journals Angiopoietin-2 concentration in serum is associated with severe asthma phenotype

2016 ◽  
Vol 12 (1) ◽  
Author(s):  
Joanna S. Makowska ◽  
Małgorzata Cieślak ◽  
Marzanna Jarzębska ◽  
Anna Lewandowska-Polak ◽  
Marek L. Kowalski
Keyword(s):  
Severe Asthma ◽  
Asthma Phenotype ◽  
Angiopoietin 2
Sign in / Sign up

Export Citation Format

Share Document